ARVN News and Press, Arvinas Inc. From 11/07/23

2023-11-07 07:59:53 ET More on Arvinas Arvinas' Potential In Treating ER+, HER2- Breast Cancer Seeking Alpha’s Quant Rating on Arvinas Historical earnings data for Arvinas Financial information for Arvinas For further details see: Arvinas G...

– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of ...

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring AR 878/875 mutations – – Interim data from the Phase 1/...

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvina...

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 Euro...

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is...

2023-09-04 01:50:02 ET Summary Arvinas focuses on protein degradation therapies, with current projects targeting breast and prostate cancers. Financially, ARVU holds robust liquidity, minimal debt, and a cash runway till 2026; combined with encouraging preliminary therapeutic resu...

2023-08-08 07:53:53 ET Arvinas press release ( NASDAQ: ARVN ): Q2 GAAP EPS of -$1.25 beats by $0.40 . Revenue of $54.5M (+61.2% Y/Y) beats by $23.52M . For further details see: Arvinas GAAP EPS of -$1.25 beats by $0.40, revenue of $54.5M beats by $23.52M

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer – – Interim data from Phase 1/2 dos...

2023-08-06 07:21:39 ET Summary Kymera Therapeutics is a clinical-stage developmental firm focused on developing small molecule therapeutics to degrade disease-causing proteins. Analysts are mixed on the shares and the stock has a large short position in the equity currently. T...